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Abstract
Objectives. To examine the incidence, prevalence and trends for opioid prescriptions in patients with OA.
Furthermore, types of opioids prescribed and long-term prescription rates were examined. Finally, the patient char-
acteristics associated with the prescription of opioids were assessed.
Methods. A population-based cohort study was conducted using the Integrated Primary Care Information data-
base. Incidence and prevalence of opioid prescriptions were calculated for the period 2008–2017. Logistic regres-
sion was used to assess which patient characteristics were associated with opioid prescriptions.
Results. In total, 157 904 OA patients were included. The overall prescription rate remained fairly stable, at around
100 incident and 170 prevalent prescriptions per 1000 person years. However, the incident prescription rate for
oxycodone increased from 7.1 to 40.7 per 1000 person years and for fentanyl from 4.2 to 7.4 per 1000 person
years. The incident prescription rate for paracetamol/codeine decreased from 63.0 to 13.3 per 1000 person years.
Per follow-up year, long-term use was found in 3% of the patients with incident OA. Finally, factors associated
with more prescriptions were increasing age, OA in 2 joint groups [odds ratio (OR) 1.56; 95% CI: 1.51, 1.65] and
the presence of other musculoskeletal disorders (OR 4.91; 95% CI: 4.76, 5.05). Men were less likely to be pre-
scribed opioids (OR 0.78; 95% CI: 0.76, 0.80).
Conclusion. Prescription rates for opioids remained stable, but types of opioids prescribed changed. Oxycodone
and fentanyl were increasingly prescribed, while prescriptions of paracetamol/codeine decreased. Since the benefit
of opioids for OA pain is questionable and side effects are common, opioids should be prescribed with caution.
Key words: osteoarthritis, pain, opioids, analgesics
Introduction
OA is one of the major chronic pain conditions of the
musculoskeletal system. Approximately 15% of the
population suffers from OA, and the Global Burden of
Disease study ranked OA as the 11th biggest contribu-
tor to global disability [1, 2]. One of the major
complaints of patients with OA is pain. Since the popu-
lation is ageing and obesity is increasing, it is expected
that the disease burden will increase [2].
Treatment options for OA pain consist of exercise
therapy, education, weight loss and pain medication,
among others. Pain medication is often prescribed in a
stepwise approach starting with paracetamol, then top-
ical and oral NSAIDs, followed by opioids if earlier steps
do not reduce the pain sufficiently. Nevertheless, the
current guidelines for the treatment of OA have a re-
strictive advice on the use of opioids for OA-related pain
[3], or do not recommend the use of opioids [4], since
the benefit for OA pain is questionable and treatment is
associated with side effects.
Rheumatology key messages
. The overall prescription rates of opioids remained stable over the past decade.
. Prescription rates of oxycodone and fentanyl have increased, while prescription rate of paracetamol/codeine
has decreased.
. Opioids were prescribed for long-term use in 3% of the patients with incident OA.
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Opioids are increasingly being prescribed for chronic
non-cancer pain. It has been estimated that around
70% of the prescribed opioids are prescribed for chron-
ic non-cancer pain. Musculoskeletal disorders, including
OA, are an important cause of non-cancer pain [5]. The
number of opioid prescriptions has risen in the US in
particular, more so than in Europe [6]. Opioids do have
a potential to cause harm and frequently have side
effects, like nausea, constipation and somnolence. In
elderly OA patients, the risk of falls and fractures is
increased when using opioids [7, 8]. Finally, misuse and
addiction are a risk when using opioids [9, 10].
Despite the questionable benefit and the frequency of
side effects, the use of opioids in OA patients is high
[11, 12] and increasing [13, 14]. Earlier research exam-
ined the total use of opioids for OA, but did not focus
on which types of opioids were used [11, 13].
Furthermore, knowledge about the long-term use of
opioids in OA is scarce.
Therefore, the aim of the current study is to examine
the incidence and prevalence of the different types of
opioids prescribed in patients with OA and the trends in
opioid prescription over the past decade. We examined
the long-term prescription rate of opioids in patients
with OA and assessed which patient characteristics are
associated with opioid prescription.
Methods
Setting
This study was conducted using the Integrated Primary
Care Information (IPCI) database. The IPCI database
contains the electronic patient records of >1.5 million
patients in the Netherlands. The database contains all
journal entries by general practitioners (GPs), diagnoses
coded according to the International Classification of
Primary Care (ICPC) codes, laboratory findings and drug
prescriptions [15, 16].
Study cohort
For this study, the use of opioids by patients with OA
and aged 30 years between 1 January 2008 and 31
December 2017 was examined. Patients who were
newly diagnosed with OA in this period (incident OA) as
well as patients with a diagnosis of OA in their medical
history (prevalent OA) were included in the cohort.
Patients with at least 12 months of valid database his-
tory prior to the study entry were included in the cohort.
The diagnosis of OA was based on the ICPC codes L84
(spinal OA), L89 (hip OA), L90 (knee OA) and L91 (other
peripheral joints affected by OA). Patients younger than
30 were excluded from the cohort (<1% of the patients
with a diagnosis of OA), because the use of these ICPC
codes in such cases was often a coding error by the GP.
Patients were excluded from the cohort if diagnosed
with or having a medical history of malignancy, neuro-
pathic pain disorders or fibromyalgia. Patients were
excluded 1 year prior to the first diagnosis of these
diseases. If follow-up of the patient was until death, they
were excluded from the cohort 1 year before their death.
The main reason for exclusion of these patient groups is
that there was a probability that opioids were prescribed
for reasons other than pain related to OA.
Outcomes
All opioid prescriptions are dispensed by GPs or clini-
cians in the Netherlands. Opioid prescriptions are identi-
fied by Anatomical Therapeutic Chemical (ATC) code.
Prescriptions for tramadol (N02AX02), tramadol/para-
cetamol (N02AJ13), paracetamol/codeine (N02AJ06/
N02BE51), oxycodone (N02AA05), fentanyl (N02AB03),
morphine (N02AA01) and buprenorphine (N02AE01)
were examined since these are commonly prescribed
opioids. Hydromorphone, tapentadol, nicomorphine and
oxycodone/naloxone were examined, but were rarely
prescribed for OA pain (<1.0 prescrition per 1000
person years) and were therefore not considered in the
analyses. Tramadol, tramadol/paracetamol and para-
cetamol/codeine were classified as weak opioids, and
oxycodone, fentanyl, morphine and buprenorphine as
strong opioids.
The incidence for opioid prescriptions was determined
as the total number of new episodes of opioid prescrip-
tions divided by the total number of person years in the
cohort per calendar year. A new opioid prescription epi-
sode was defined as no prescription in the preceding
6 months. The prevalence of opioid prescriptions was
calculated as the total number of patients who had at
least one prescription of opioids divided by the total
number of person years in the cohort in a calendar year.
New episodes of opioid prescriptions within 6 months of
a diagnosis of a trauma (e.g. fracture) were excluded in
both calculations since it was less likely that those pre-
scriptions were for OA-related pain. Those patients
remained in the cohort.
For the patients with incident OA, the number of differ-
ent types of opioids that were prescribed and the order in
which they were prescribed were examined. If patients
switched back to an opioid that had been prescribed pre-
viously, we did not count this as a new type of opioid.
Furthermore, the percentage of patients with incident OA
who were prescribed opioids over a long term was calcu-
lated. Long-term prescription of opioids was defined as
six or more prescriptions during one follow-up year (i.e. in
the first year after diagnosis, in the second year after diag-
nosis, etc.). The median duration of a prescription for
opioids is 15 days in the IPCI database and other data-
bases [17]. Therefore, six prescriptions corresponds to an
estimated 90 days of opioid use in a year.
Statistical analyses
Descriptive statistics were performed to give the base-
line characteristics of the cohort and to calculate preva-
lence and incidence rates of opioid prescriptions.
Univariate logistic regression analyses were conducted
to examine whether baseline characteristics were
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related to opioid prescription, and odds ratios (ORs) and
their 95% CI were calculated. Variables were included in
the multivariate analysis if P<0.1 in the univariate ana-
lysis. All analyses were performed using SPSS Statistics
version 24 (IBM Corp., Armonk, NY, USA).
Study approval
The study was approved by the Board of Directors of
the IPCI database.
Results
Study population
In total, 157 904 patients were included in the cohort
(Table 1). Of these, 56 713 were newly diagnosed with
OA. Of the total patient group, 65.2% were female. Co-
morbidities were present in 55.2% of the patient group.
The most common type of OA was knee OA (27.8%)
and 21.3% of the patients were diagnosed with OA in
more than one joint group. At the start of the follow-up
period, the mean age was 66.6 (S.D. 12.5) years. During
the follow-up period, 65% of the patients visited the GP
with another musculoskeletal complaint besides OA
(mean follow-up duration was 3 years and 4 months).
Trends in incident opioid prescription rate
In the past decade, the overall incident prescription rate
for opioids remained fairly stable (Fig. 1). However, the
prescription rate for strong opioids was increasing while
the prescription rate for weak opioids was decreasing
(Figure 2, numbers in Supplementary Table S1, available
at Rheumatology online). The incident prescription rate
for oxycodone increased from 7.1 per 1000 person
years in 2008 to 40.7 per 1000 person years in 2017
and the incident rate for fentanyl increased from 4.2 to
7.4 per 1000 person years. The prescription rate for tra-
madol/paracetamol decreased from 22.3 to 18.4 per
1000 person years and the prescription rate for para-
cetamol/codeine decreased between 2008 and 2017
from 63.0 to 13.3 per 1000 person years. In 2013, health
insurance companies stopped reimbursing the costs of
paracetamol/codeine, which led to the rapid decline
since then [18]. The prescription rates for tramadol, mor-
phine and buprenorphine remained stable over the past
decade. Buprenorphine was introduced to the market in
2007.
Trends in prevalent opioid prescription rate
The trends in prevalent opioid prescription rates showed
similar patterns to the incident prescription rates. The
overall rate of prescriptions remained stable, while the
prescription rate for strong opioids increased and the
prescription rate for weak opioids decreased (Figure 2,
numbers in Supplementary Table S1, available at
Rheumatology online). The major changes were the in-
crease in the prevalent prescription rate for oxycodone
from 11.1 to 50.7 per 1000 person years and the
decrease in the rate for paracetamol/codeine from 99.1
to 20.1 per 1000 person years.
Long-term prescriptions
In each follow-up year after the diagnosis of OA, 3% of
the patients were prescribed opioids over a long term
(6 prescriptions), representing around a quarter of the
patients prescribed any opioid in a given year (Table 2).
When comparing strong opioids with weak opioids, the
percentage of patients prescribed opioids over a long
term was twice as high for patients prescribed strong
TABLE 1 Baseline characteristics
Characteristic Value (n5 157 904)
Age, mean (S.D.), years 66.6 (12.5)
Age category, n (%)
30–39 2587 (1.6)
40–49 11 593 (7.3)
50–59 31 409 (19.9)
60–69 46 924 (29.7)
70–79 39 172 (24.8)
80–89 22 640 (14.3)
90 3579 (2.3)
Female, n (%) 102 988 (65.2)
Joints affected, n (%)
Back 16 409 (10.4)
Hip 27 508 (17.4)
Knee 43 919 (27.8)
Other joints 36 410 (23.1)
Two or more joints 33 658 (21.3)
Diabetes, n (%) 22 763 (14.4)
Hypertension, n (%) 63 481 (40.2)
Hyperlipidaemia, n (%) 27 218 (17.2)
MI/AP, n (%) 17 073(10.8)
Stroke/TIA, n (%) 5869 (3.7)
PAD, n (%) 5585 (3.5)
UGI/ulcer, n (%) 5027 (3.2)
Heart failure, n (%) 6306 (4.0)
Inflammatory arthritis, n (%) 7091 (4.5)
Other MSD during cohort timea, n (%)
Upper extremity 36 293 (23.0)
Lower extremity 57 131 (36.2)
Back/neck 47 529 (30.1)
Trauma 18 495 (11.7)
Other musculoskeletal 45 941 (29.1)
None 54 170 (34.3)
Renal function, n (%)
eGFR >60 ml/min 98 928 (62.7)
eGFR 30–60 ml/min 18 298 (11.6)
eGFR <30 ml/min 1 613 (1.0)
Missing 39 065 (24.7)
aNon-specific ICPC diagnoses for complaints of the mus-
culoskeletal system, for example shoulder or hip com-
plaints. The group of back/neck symptoms also includes
radiculopathy. AP: angina pectoris; eGFR: estimated glom-
erular filtration rate; ICPC: International Classification of
Primary Care; MI: myocardial infarct; MSD: musculoskeletal
disorders; PAD: peripheral arterial disease; TIA: transient
ischaemic attack; UGI: upper gastrointestinal.
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opioids than for patients prescribed a weak opioid.
Furthermore, these percentages did not change with
increasing follow-up years.
Different types of opioids prescribed
Almost 75% of the patients with incident OA were not
prescribed an opioid during the follow-up period
(Figure 3A). Of the patients with incident OA, 18.4%
were prescribed one type of opioid. A switch to another
opioid was made in 8.8% of the patients. Two different
types of opioids were prescribed for 5.7% of the
patients and 2.1% were prescribed 3 types of opioids.
Of all patients, 16.4% were prescribed a weak opioid,
5.1% a strong opioid and 4.6% were prescribed both
categories. The most common first opioid prescribed to
patients was tramadol (39.7%). Oxycodone was pre-
scribed as the first opioid in 17.2% of cases (Figure 3B
and Supplementary Table S2, available at Rheumatology
online).
Characteristics associated with opioid prescription
In both the univariate and the multivariate regression
analyses, the prescription of opioids was associated
with a more advanced age at the baseline of the cohort
and men were less likely to be prescribed opioids than
women (OR 0.78; 95% CI: 0.76, 0.80) (Table 3). Patients
with two or more joint groups involved were more likely
to be prescribed opioids (OR 1.97; 95% 1.89, 2.05),
while patients with OA in other peripheral joints (ICPC
code L91) were less likely to be prescribed opioids (OR
0.74; 95% CI: 0.71, 0.78) than patients with back OA.
The diagnosis of other musculoskeletal disorders during
the follow-up period was associated with the prescrip-
tion of opioids. Concomitant neck and back problems
(OR 3.41; 95% CI: 3.25, 3.57) and the presence of mul-
tiple musculoskeletal disorders (OR 4.91; 95% CI: 4.76,
5.05) in particular were associated with a greater likeli-
hood of opioid prescriptions.
Discussion
In this study we examined the trends, the long-term pre-
scription and the factors associated with the prescription
of opioids in patients with OA. The majority of patients
with OA were not prescribed an opioid during the follow-
up period. The overall prescription rate of opioids
remained fairly stable in the period between 2008 and
2017, with on average 100 incident prescriptions per
1000 person years and 170 prevalent prescriptions per
1000 person years. However, there was a change in the
types of opioids that were prescribed. Over time, strong
opioids were increasingly prescribed, while prescriptions
of weak opioids declined. The prescription rate of
FIG. 1 Total opioid prescription rate
PY: patient years.
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oxycodone increased rapidly in this decade from 7.1 to
40.7 incident prescriptions per 1000 person years. The
prescription rate for fentanyl also increased from 4.2 to
7.4 incident prescriptions per 1000 person years, while
the prescription rates for paracetamol/codeine and tra-
madol/paracetamol decreased. Weak opioids are still
FIG. 2 Incidence and prevalence of prescribed opioids
(A) Weak opioids; (B) strong opioids. PY: patient years.
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most frequently prescribed for OA-related pain. Around
3% of the patients with incident OA were prescribed
opioids over a long term per follow-up year. Finally, fac-
tors associated with a greater likelihood of more opioid
prescriptions were female sex, increasing age, OA in two
or more joint groups, and the presence of other musculo-
skeletal disorders besides OA.
Most of the studies examining opioid prescriptions in
OA patients found an increase in the prescription rate
[12–14, 19] while we found a relatively stable prescrip-
tion rate. One study looking at US insurance data claims
also found a relatively stable opioid prescription rate
[20]. However, oxycodone is increasingly being pre-
scribed for patients with OA according to the present
study. This is in agreement with other studies, which
also found increases in the prescription rate of oxy-
codone for OA [12] and strong opioids for musculoskel-
etal pain in general [21]. At the same time as the
prescription rates for oxycodone and fentanyl increased,
the prescription rates for paracetamol/codeine and tra-
madol/paracetamol decreased. The decline in prescrip-
tions for paracetamol/codeine was caused by the end to
reimbursement of the costs by the health insurance
companies [18]. This simultaneous increase and de-
crease could be a coincidence since the increase in
strong opioids is also seen in other countries, but it
might also be that GPs are prescribing strong opioids
instead of weak opioids. Furthermore, the awareness for
cardiovascular and gastrointestinal risks of NSAIDs has
increased in the past decade and NSAIDs are pre-
scribed less in patients with musculoskeletal disorders
[22, 23]. This may also have influenced the prescription
rates of (strong) opioids.
The prevalent prescription rate for all opioids was
around 170 per 1000 person years in our study. This
number is slightly lower than in some other studies [11,
24]. Prescription rates of opioids in general in the
Netherlands are lower than or comparable to the pre-
scription rates in the countries covered by these studies
(e.g. USA, Sweden and Spain) [6]. Some studies found
lower prescription rates for opioids, but these studies
did not include tramadol [20] or included only the most
commonly prescribed opioids (e.g. tramadol and fen-
tanyl) [13] in the analyses.
Most patients with incident OA were prescribed a
weak opioid as their first opioid, which is in line with the
current guidelines in the Netherlands [25]. Furthermore,
a switch in the type of opioid prescribed was made in
8.8% of the patients with incident OA. A recent study in
patients with chronic musculoskeletal pain in the UK
also found that weak opioids were most frequently pre-
scribed and that a third of the patients used two or
more different opioids. This higher percentage of
patients using multiple types of opioids may be because
the latter study only included patients with chronic pain.
In the Dutch GP guidelines, strong opioids are advised
after the prescription of weak opioids [25]. However, al-
most a quarter of the patients with incident OA were dir-
ectly prescribed a strong opioid.
Around 3% of the patients with incident OA were pre-
scribed opioids over a long term (6 prescriptions per
follow-up year). No previous data on long-term use
specific to OA is available to our knowledge, but this
percentage is comparable to long-term use in
FIG. 3 Types of opioids prescribed in patients with inci-
dent OA
(A) Types of opioids prescribed in patients with
incident OA, including patients not prescribed opioids.
(B) Sequence of types of opioids prescribed in patients
with incident OA. n¼56 713. The inner circle represents
the first opioid prescribed, the second circle the se-
cond type of opioid prescribed and the outer circle the
third type of opioid prescribed. Percentages are shown
in parentheses. BUP (dark blue): buprenorphine; FTY
(turquoise): fentanyl; MOP (orange): morphine; OXY
(purple): oxycodone; PCM/COD (red): paracetamol/co-
deine; TRA (blue): tramadol; TRA/PCM (green): trama-
dol/paracetamol.
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musculoskeletal disorders in general [26, 27]. We did
not find an increase in long-term use with increasing
follow-up time. Analyses per calendar year showed simi-
lar results (data not shown). The available evidence on
whether long-term use of opioids for musculoskeletal
disorders is increasing gives conflicting results [26, 27].
Factors associated with opioid prescription were
increasing age, female sex, the presence of other
musculoskeletal disorders and multiple joint groups
affected by OA. These characteristics are also found in
other studies [14, 28, 29]. The higher prescription rates
in older patients is concerning since use of opioids in
this group is associated with more severe side effects
like falls and fractures [7, 8].
The high rates and long-term use of opioids for OA
pain are concerning since the absolute number of
TABLE 3 Factors associated with opioid prescription
Factor Patients prescribed
opioid, n (%)
Univariate analysis,
OR (95% CI)
Multivariate analysis,
OR (95% CI)
Age category
30–39 495 (19.1) 1
40–49 2902 (25.0) 1.41 (1.27, 1.57) 1.30 (1.17, 1.46)
50–59 8106 (25.8) 1.47 (1.33, 1.63) 1.29 (1.16, 1.44)
60–69 12 263 (26.1) 1.50 (1.35, 1.65) 1.32 (1.19, 1.46)
70–79 12 036 (30.7) 1.88 (1.79, 2.07) 1.57 (1.41, 1.74)
80–89 7305 (32.3) 2.01 (1.82, 2.23) 1.73 (1.55, 1.92)
>90 1036 (28.9) 1.72 (1.52, 1.95) 1.72 (1.52, 1.96)
Sex
Female 31 383 (30.5) 1
Male 12 760 (23.2) 0.69 (0.67, 0.71) 0.78 (0.76, 0.80)
Joint affected
Spine 4273 (26.0) 1
Hip 7172 (26.1) 1.00 (0.96, 1.05) 1.05 (1.00, 1.09)
Knee 11 266 (25.7) 0.98 (0.94, 1.02) 1.02 (0.98, 1.07)
Other joints 7641 (21.0) 0.75 (0.72, 0.79) 0.75 (0.71, 0.78)
2 joints 13 791 (41.0) 1.97 (1.89, 2.05) 1.58 (1.51, 1.65)
MSD
None 7667 (13.4) 1
Upper extremity 1591 (21.6) 1.78 (1.67, 1.89) 1.79 (1.69, 1.91)
Lower extremity 3916 (23.9) 2.03 (1.94, 2.12) 1.94 (1.86, 2.02)
Neck/back 11 451 (34.4) 3.38 (3.23, 3.54) 3.41 (3.25, 3.57)
Other MSD 2542 (24.6) 2.11 (2.00, 2.22) 2.09 (1.99, 2.20)
2 MSD categories 24 489 (44.3) 5.14 (4.99, 5.29) 4.91 (4.76, 5.05)
Values in bold are statistically significant. MSD: musculoskeletal disorder.
TABLE 2 Chronic users of opioids per follow-up year
Follow-up time (year) Total n (% users/%
population)
Weak opioids n
(% users/% population)
Strong opioids n
(% users/% population)
1 1659 (21.5/3.9) 1025 (16.4/2.5) 590 (26.4/1.4)
2 996 (22.1/3.2) 601 (16.2/1.9) 366 (30.0/1.2)
3 709 (23.7/3.2) 401 (16.8/1.8) 275 (30.8/1.2)
4 440 (22.8/3.0) 234 (15.5/1.6) 195 (33.0/1.3)
5 276 (23.6/3.1) 142 (15.1/1.6) 130 (35.2/1.5)
6 159 (24.6/3.4) 82 (16.7/1.7) 72 (33.2/1.5)
7 81 (27.5/3.8) 34 (15.7/1.6) 45 (37.8/2.1)
8 38 (31.4/4.1) 20 (21.5/2.1) 18 (37.5/1.9)
9 13 (29.5/4.9) 7 (22.6/2.6) 6 (33.3/2.2)
A chronic user of opioids has 6 prescriptions in 1 follow-up year. The number of total chronic users does not equal the
sum of the chronic users of weak and strong opioids. Patients can be included in both categories or can be included in
the group of total users if the sum of prescriptions for weak and strong opioids is 6 while the use of weak opioids only
or strong opioids only is not classified as chronic use.
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patients is high. As mentioned earlier, guidelines have a
restrictive advice on the use of opioids [3, 4].
Furthermore, a recent study showed that treatment with
opioids for patients with OA or for patients with low
back pain did not result in better pain relief than treat-
ment with non-opioid analgesics (e.g. paracetamol and
NSAIDs) [30]. In addition, long-term use is associated
with dose-dependent adverse events, like trauma and
addiction [7, 31], and does not lead to an improved
quality of life [32].
A strength of the current study is that it was con-
ducted using a database that is a representative sample
of the Dutch population. That is because in the
Netherlands most opioids are prescribed by the GP.
Initial data show that around 70% of the first prescrip-
tions and around 90% of the repeat prescriptions of
opioids are prescribed by the GP [33].
There are several limitations to this study. Firstly,
patients were only included in the cohort if diagnosed
with OA. Since GPs vary in how strictly they apply the
ICPC codes, this may have led to an overestimation or
underestimation of patients with OA. Studies using UK
primary healthcare databases showed that the positive
predictive value of hip OA codes is sufficiently high [34],
but that OA is probably under-recorded [35].
Furthermore, in the medical records the indication of the
opioid prescription could not be directly linked to a
diagnosis. We excluded patients with malignancy,
neuropathic pain disorders or fibromyalgia and patients
in the year before death. Nevertheless we cannot rule
out the possibility that some opioid prescriptions will be
for reasons other than OA-related pain. We did not ex-
clude all other musculoskeletal comorbidities for which
opioids can be prescribed. These are frequently present
in OA patients [36] and we found that the presence of
musculoskeletal comorbidities was positively associated
with opioid prescriptions.
To conclude, the overall prescription rate of opioids
remained fairly stable in the past decade. However, the
prescription rate for oxycodone increased rapidly and
the prescription rate for fentanyl almost doubled, while
the prescription rates for paracetamol/codeine and tra-
madol/paracetamol decreased. Weak opioids are more
commonly prescribed for OA pain than strong opioids.
The increase in prescriptions of strong opioids is con-
cerning since clinically relevant effectiveness is ques-
tionable for OA pain and serious side effects are
common. Therefore, opioids should be prescribed with
caution, especially for long-term use, and alternative
strategies for reducing pain and for reducing long-term
opioid use should be considered.
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